Gland Pharma receives approval for Acetaminophen Injection

Gland Pharma Limited (Gland or Company), a generic injectable-focused pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for Acetaminophen Injection, 10 mg/mL (500mg/50mL and 1000mg/100mL) Bags.

The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Acetaminophen Injection, 500 mg/50 mL (10 mg/mL) and 1000 mg/100 mL (10 mg/mL), of B. Braun Medical, Inc.

This Product is indicated for the management of mild to moderate pain in adult and pediatric patients 2 years and older, as well as moderate to severe pain with adjunctive opioid analgesics in adult and pediatric patients 2 years and older.

The Company expects to launch this Product through its marketing partner in the near future. According to IQVIA, the product had US sales of approximately USD 55 million for the twelve months ending February 2025.

Shares of Gland Pharma Limited was last trading in BSE at Rs. 1535.10 as compared to the previous close of Rs. 1555.05. The total number of shares traded during the day was 3058 in over 605 trades.

The stock hit an intraday high of Rs. 1589.95 and intraday low of 1527.10. The net turnover during the day was Rs. 4701553.00.

Source : Equity Bulls

Keywords

GlandPharma INE068V01023 USFDA Approval AcetaminophenInjection